Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;49(1):300060520982657.
doi: 10.1177/0300060520982657.

Evaluation of main functional dyspepsia symptoms after probiotic administration in patients receiving conventional pharmacological therapies

Lorenzo Drago  1 , Gabriele Meroni  1 , Dario Pistone  1 , Luigi Pasquale  2 , Giuseppe Milazzo  3 , Fabio Monica  4 , Salvatore Aragona  5 , Leonardo Ficano  6 , Roberto Vassallo  7 ; Gastrobiota Group
Affiliations

Evaluation of main functional dyspepsia symptoms after probiotic administration in patients receiving conventional pharmacological therapies

Lorenzo Drago et al. J Int Med Res. 2021 Jan.

Abstract

Objective: Postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) are the two main forms of functional dyspepsia (FD). Probiotics are a promising therapy for FD, but current data remains heterogeneous. This work aims to evaluate a probiotic combination of Lacticaseibacillus rhamnosus LR04 (DSM 16605), Lactiplantibacillus pentosus LPS01 (DSM 21980), Lactiplantibacillus plantarum LP01 (LMG P-21021), and Lactobacillus delbrueckii subsp. delbruekii LDD01 (DMS 22106), alone or together with other pharmacological therapies, for clinical improvement of symptoms associated with FD.

Methods: Patients with FD were enrolled and divided into two groups: PDS and EPS. Probiotic alone or combined with prokinetics, antacids, or proton-pump-inhibitors were administered for 30 days. A progressive-score scale was used to evaluate symptoms in all patients at the beginning of the trial and at 15 days after the end of treatment.

Results: A cohort of 2676 patients were enrolled (1 357 with PDS; 1 319 with EPS). All patients showed significant improvements in dyspeptic symptoms following treatment. In patients with PDS, probiotic alone resulted in the lowest prevalence of symptoms following treatment, while patients with EPS showed no clear between-treatment differences.

Conclusions: Dyspeptic symptoms were reduced following treatment in all patients.

Keywords: Dyspepsia; Functional disorders; Probiotics.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All authors received grants for analysis of data in the present study, and as members of the Advisory Board for Aurora Biofarma and for Probiotical.

Figures

Figure 1.
Figure 1.
Analysis of postprandial filling and early satiety in patients with postprandial distress syndrome treated for 30 days with one of four pharmacological combinations: (a and b) probiotic alone; (c and d) probiotic plus proton-pump inhibitor; (e and f) probiotic plus prokinetics; and (g and h) probiotic plus antacid. T0, baseline timepoint; T1, 15 days following completion of 30-day treatment period; A, absent; Ml, mild; D, discreet; Md, moderate; S, severe; PPI, proton-pump inhibitor; PKT, prokinetics; ATC, antacids: *P ≤ 0.05; **P < 0.01; ***P < 0.001.
Figure 2.
Figure 2.
Analysis of epigastric pain and epigastric burning in patients with epigastric pain syndrome treated for 30 days with one of four pharmacological combinations: (a and b) probiotic alone; (c and d) probiotic plus proton-pump inhibitor; (e and f) probiotic plus prokinetics; and (g and h) probiotic plus antacid. T0, baseline timepoint; T1, 15 days following completion of 30-day treatment period; A, absent; Ml, mild; D, discreet; Md, moderate; S, severe; PPI, proton-pump inhibitor; PKT, prokinetics; ATC, antacids: *P ≤ 0.05; **P < 0.01; ***P < 0.001.
Figure 3.
Figure 3.
Comparison of the prevalence of absence of symptoms following treatment (T1) between different therapy groups in patients with (a) postprandial distress syndrome (group a); and (b) epigastric pain syndrome (group b). PPF, postprandial filling; ES, early satiety; EP, epigastric pain; EB, epigastric burning; AS, abdominal swelling; PPI, proton-pump inhibitor; PKT, prokinetics; ATC, antacids: *P ≤ 0.05; **P < 0.01; ***P < 0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Talley NJ. Functional dyspepsia: advances in diagnosis and therapy. Gut Liver 2017; 11: 349–357. - PMC - PubMed
    1. Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology 2016; 150: 1380–1392. - PubMed
    1. Stanghellini V. Functional dyspepsia and irritable bowel syndrome: beyond Rome IV. Dig Dis 2017; 35: 14–17. - PubMed
    1. Kim SE, Kim N, Lee JY, et al. Prevalence and risk factors of functional dyspepsia in health check-up population: a nationwide multicenter prospective study. J Neurogastroenterol Motil 2018; 24: 603–613. - PMC - PubMed
    1. Ahyani T, Supriatmo S, Deliana M, et al. Lactobacillus probiotics for treating functional dyspepsia in children. Paediatr Indones 2016; 56: 37–42.

Substances